117 related articles for article (PubMed ID: 2323626)
1. Mafosfamide induces less sister chromatid exchange in Ph-positive cells than in normal bone marrow.
Becher R; Becker G; Schmidt CG
Haematol Blood Transfus; 1990; 33():133-6. PubMed ID: 2323626
[TBL] [Abstract][Full Text] [Related]
2. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging.
Douay L; Hu C; Giarratana MC; Bouchet S; Conlon J; Capizzi RL; Gorin NC
Blood; 1995 Oct; 86(7):2849-55. PubMed ID: 7670119
[TBL] [Abstract][Full Text] [Related]
3. Successful mafosfamide purging of bone marrow from chronic myelogenous leukemia (CML) cells.
Nieborowska-Skórska M; Skórski T; Ratajczak MZ; Szczylik C; Malaguarnera L; Calabretta B
Folia Histochem Cytobiol; 1993; 31(4):161-7. PubMed ID: 8137996
[TBL] [Abstract][Full Text] [Related]
4. Mafosfamide (ASTA-Z-7654) in vitro treatment of bone marrow does not eradicate Philadelphia-positive cells in chronic myeloid leukaemia.
Mortensen BT; Ernst P; Philip P
Eur J Haematol; 1988 Sep; 41(3):218-22. PubMed ID: 3181395
[TBL] [Abstract][Full Text] [Related]
5. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
[TBL] [Abstract][Full Text] [Related]
6. Fractionation of chronic myelogenous leukemia marrow cells by stroma adherence: implications for marrow purging.
Rizzoli V; Mangoni L; Piovani G; Garau D; Caramatti C; Almici C; Carlo-Stella C
Leuk Lymphoma; 1993; 11 Suppl 1():109-12. PubMed ID: 8251884
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
[TBL] [Abstract][Full Text] [Related]
8. Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide.
Skorski T; Nieborowska-Skorska M; Barletta C; Malaguarnera L; Szcyzlik C; Chen ST; Lange B; Calabretta B
J Clin Invest; 1993 Jul; 92(1):194-202. PubMed ID: 8325984
[TBL] [Abstract][Full Text] [Related]
9. Induction of sister chromatid exchanges and chromosomal aberrations by busulfan in Philadelphia chromosome-positive chronic myeloid leukemia and normal bone marrow.
Becher R; Prescher G
Cancer Res; 1988 Jun; 48(12):3435-9. PubMed ID: 3163516
[TBL] [Abstract][Full Text] [Related]
10. Autologous transplantation for chronic myelogenous leukemia with mafosfamide-treated marrow.
Rizzoli V; Mangoni L; Almici C; Caramatti C; Dotti GP; Carlo-Stella C
Stem Cells; 1993 Oct; 11 Suppl 3():25-30. PubMed ID: 8298474
[TBL] [Abstract][Full Text] [Related]
11. In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocyte--macrophage colony-stimulating factor.
Carlo-Stella C; Mangoni L; Piovani G; Almici C; Garau D; Caramatti C; Rizzoli V
Bone Marrow Transplant; 1991 Oct; 8(4):265-73. PubMed ID: 1756324
[TBL] [Abstract][Full Text] [Related]
12. Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide.
Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Cottafavi L; Dotti GP; Rizzoli V
Bone Marrow Transplant; 1994 Sep; 14(3):425-32. PubMed ID: 7994267
[TBL] [Abstract][Full Text] [Related]
13. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells.
Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Rizzoli V
Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323
[TBL] [Abstract][Full Text] [Related]
14. Biclonal analysis of busulfan-induced sister chromatid exchange in blast crisis of Philadelphia chromosome-positive chronic myeloid leukemia.
Becher R; Prescher G
Cancer Genet Cytogenet; 1991 Mar; 52(1):71-8. PubMed ID: 2009513
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of doxorubicin in combination with mafosfamide for in vitro elimination of myeloid and lymphoid tumor cells from human bone marrow.
Domenech J; Georget MT; Gihana E; Colombat P; Brémond JL; Chassaigne M; Lamagnère JP; Binet C
Bone Marrow Transplant; 1992 Feb; 9(2):101-6. PubMed ID: 1571708
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging.
Stilz R; Grünebach F; Bader P; Vogel W; Kanz L; Brugger W; Scheding S
J Hematother Stem Cell Res; 2001 Dec; 10(6):777-85. PubMed ID: 11798504
[TBL] [Abstract][Full Text] [Related]
17. The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells.
Gidáli J; Fehér I
Bone Marrow Transplant; 1992 Dec; 10(6):479-83. PubMed ID: 1490197
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological-mediated purging with mafosfamide in acute and chronic myeloid leukemias. The Italian Study Group.
Rizzoli V; Mangoni L
Prog Clin Biol Res; 1990; 333():21-36; discussion 37-8. PubMed ID: 2308982
[TBL] [Abstract][Full Text] [Related]
19. [Bone marrow autograft treated with mafosfamide in the acceleration phase in chronic myeloid leukemia. Inversion of the clinical development].
Fouillard L; Van Den Akker J; Laporte JP; Najman A; Perot C; Lopez M; Douay L; Isnard F; Taillemite JL; Gorin NC
Presse Med; 1989 Nov; 18(36):1785-8. PubMed ID: 2530566
[TBL] [Abstract][Full Text] [Related]
20. ASTA Z 7557 (INN mafosfamide) for the in vitro treatment of human leukemic bone marrows.
Douay L; Gorin NC; Laporte JP; Lopez M; Najman A; Duhamel G
Invest New Drugs; 1984; 2(2):187-90. PubMed ID: 6381382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
